#ESMO21: Proffered Paper session - Genitourinary tumours, prostate

ESMO
9/18/21, 4:30 PM
Europe/Paris GMT+2

Description

#ESMO21 Sat, 18.09.2021

Time

13:30 - 14:50 LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study

Presentation Number

LBA24

Speakers

Neeraj Agarwal (Salt Lake City, United States of America)

Lecture Time

13:30 - 13:40

 

Invited Discussant LBA24

Speakers

Cora N. Sternberg (New York, United States of America)

Lecture Time

13:40 - 13:50

 

Q&A and live discussion

Lecture Time

13:50 - 13:55

 

577O - PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Presentation Number

577O

Speakers

Shahneen K. Sandhu (Melbourne, VIC, Australia)

Lecture Time

13:55 - 14:05

 

Invited Discussant 577O

Speakers

Joaquin Mateo (Barcelona, Spain)

Lecture Time

14:05 - 14:15

 

Q&A and live discussion

Lecture Time

14:15 - 14:20

 

LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Presentation Number

LBA25

Speakers

Andrew J. Armstrong (Durham, United States of America)

Lecture Time

14:20 - 14:30

 

Invited Discussant LBA25

Speakers

Stephane M. Oudard (Paris, France)

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study, Invited Discussant LBA24, Q&A and live discussion, PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC), LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Inglês

 

Speakers

Neeraj Agarwal, Cora N. Sternberg, Shahneen K. Sandhu, Joaquin Mateo, Andrew J. Armstrong, Stephane M. Oudard

 

Link to the Event

Banner to the Event

#ESMO21: Proffered Paper session - Genitourinary tumours, prostate